An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.
Retinal drug toxicity and efficacy
Retinal drug toxicity is a relatively uncommon occurrence but with potential life-changing impact for patients. Most in vitro pre-clinical models for testing drug safety and efficacy are poor representations of the complex human retina. Newcells iPSC-derived retinal organoids and RPE is a platform used for more accurate in vitro to in vivo extrapolation (IVIVE). It also enables screening of new drugs and therapies for the retina.
- Modelling retinal drug toxicity: this has been tested for the response to known toxins such as thioridazine and doxorubicin. The intrinsic fluorescence of doxorubicin facilitates visualisation of the drug penetration. (A) Exposure of the iPSC-derived retinal organoids to doxorubicin reduces cell viability in a dose-dependent manner (B).
- Screening Tool: Newcells retinal organoids can be used for in vitro drug screening during drug development to evaluate retinal toxicity. The dose response of a drug can be measured with retinal organoids showing an effect for cytotoxic drugs, while known non-toxic drugs do not affect organoid viability (C).
More information on the retinal platform
Have any questions? Check out our Frequently Asked Questions.